How to perform OQ and PQ validation on a new capsule filling machine

Australia's pharmaceutical manufacturing sector relies on rigorous qualification protocols to keep medicines safe, effective, and compliant with the Therapeutic Goods Administration's standards. For Sydney and Melbourne-based contract manufacturers and the growing number of compounding facilities in Brisbane and Perth, validating new equipment is not optional; it is the backbone of a defensible quality system. A capsule filling machine, regardless of brand or throughput, must demonstrate that it operates consistently and produces dosage units that meet every predetermined specification before any commercial batch is released.

Operational qualification (OQ) and performance qualification (PQ) sit at the centre of that validation work. OQ confirms that the installed machine functions as designed across its operating ranges, while PQ proves that the equipment performs reliably under real production conditions using actual raw materials and trained operators. Executing both stages thoroughly protects patients, satisfies auditors, and provides the documented evidence that TGA inspectors expect during routine GMP inspections and pre-approval audits.

The qualification framework in pharmaceutical manufacturing

Qualification follows a staged lifecycle that begins well before the machine arrives on the factory floor. Installation qualification (IQ) verifies that the equipment has been delivered, installed, and configured correctly, including utility connections, software loads, and calibration certificates. Only after IQ documentation is signed off should the validation team turn to OQ, which exercises the machine's functional capabilities and challenge tests its alarm systems, safety interlocks, and operating limits.

PQ follows OQ and is sometimes confused with it, but the two serve fundamentally different purposes. OQ uses calibrated instruments and placebo materials in a controlled environment to demonstrate mechanical and control system performance. PQ uses production-grade capsules, the actual API or formulation intended for market, and the operators who will routinely run the line. This distinction matters in Australia, where PIC/S-aligned GMP Annex 15 explicitly requires both phases to be completed before commercial release, and where TGA inspectors routinely examine whether PQ batches were truly representative of routine manufacturing.

Preparing for operational qualification

Preparation determines whether an OQ runs smoothly or becomes a drawn-out scramble. The validation protocol must be drafted, reviewed, and approved before any testing begins, and it should reference the manufacturer's design specifications, the user requirement specification (URS), and any functional specifications that were agreed during procurement. For Australian manufacturers importing equipment from Shanghai, this often means translating or mapping Chinese factory documentation into a format that satisfies local expectations.

A practical preparation checklist should include calibration status of all test instruments, confirmation that IQ documentation is complete, training records for the validation team, and a clear list of the operating ranges to be challenged. If the machine includes servo-driven dosing stations, weight control feedback loops, or vision-based reject mechanisms, each subsystem needs its own acceptance criteria. Many Sydney-based validation specialists recommend building the OQ test script as a series of modular sections so that a single failure does not invalidate the entire run.

Another preparation step that is sometimes overlooked is risk assessment. The validation team should identify the critical quality attributes (CQAs) and critical process parameters (CPPs) that the capsule filling machine will control, then map each to a specific OQ test. Fill weight uniformity, individual weight variation, dissolution rate, and microbiological contamination risk should each have an associated challenge test with pre-defined acceptance limits based on pharmacopoeial standards such as the British Pharmacopoeia or the United States Pharmacopoeia, both of which are accepted by the TGA.

Executing the OQ test sequence

Once preparation is complete, the OQ phase typically unfolds over several days of structured testing. The first tests address machine functionality when empty: motor rotation direction, guard interlock response, emergency stop activation, vacuum pressure ranges, and the accuracy of the touchscreen HMI. Each test should be documented with a unique identifier, the actual result measured, the expected acceptance range, and the signature of the operator and witness.

The next block of testing focuses on the machine's operating ranges using placebo or formulation-equivalent material. Common challenges include running the machine at minimum, target, and maximum speeds; testing fill weight accuracy across all dosing stations; verifying that tamping force or dosing disc settings produce consistent capsule separation; and confirming that dust extraction systems maintain particulate levels below the defined threshold. For manufacturers supplying the Australian market, this is also a good moment to verify that the machine can run the capsule sizes most commonly used locally, including size 0, size 1, and size 3.

Challenge testing for alarm and fault conditions is often the part of OQ that reveals design weaknesses. Engineers should deliberately simulate sensor failures, jammed capsule bodies, missing caps, and out-of-specification vacuum levels to confirm that the machine shuts down safely and produces clear alarm messages. Documenting these scenarios proves that the safety systems are robust and provides auditors with concrete evidence that patient risk has been considered.

Moving from operational to performance qualification

The transition from OQ to PQ should not be a formality. Before PQ begins, the validation team must close out any deviations raised during OQ, confirm that all change controls have been finalised, and verify that the standard operating procedures (SOPs) for routine operation, cleaning, and maintenance are in place and have been trained out to the production staff. In Brisbane and Adelaide facilities, where cross-functional training is often compressed by smaller headcount, this step can easily be underestimated.

PQ batches should be planned to reflect commercial reality. The number of consecutive batches typically ranges from three to five, depending on the complexity of the product and the company's validation policy. Each batch should be manufactured using the same formulation, equipment train, and operators who will be responsible for ongoing production. Sampling plans should follow a statistical rationale, and testing should cover every CQA, including assay, content uniformity, dissolution, microbial limits, and physical attributes such as brittleness and locking length.

A useful practice adopted by several Australian manufacturers is to schedule PQ runs at different times of day and across multiple shifts. This introduces variation in environmental conditions and operator technique, strengthening the evidence that the process remains in control under realistic conditions. Any out-of-specification result during PQ must trigger a formal investigation, and the batch may need to be repeated once the root cause is resolved and corrective actions verified.

Documenting results and maintaining the validated state

Documentation is the deliverable that auditors actually examine. Every test sheet, raw data printout, and calibration record should be captured in a validation report that mirrors the protocol structure, making it easy for a TGA inspector to follow the logic from test design through to final disposition. The report should include an executive summary, a list of deviations, a conclusion that explicitly states whether acceptance criteria were met, and an approval page with signatures from quality, engineering, and production representatives.

Maintaining the validated state after PQ completion requires ongoing vigilance. Periodic review, also known as the annual product quality review or the equipment validation lifecycle review, should confirm that no undocumented changes have been made to the machine, its software, or its operating environment. Change control procedures must capture even minor adjustments, such as replacing a servo drive or updating HMI firmware, and revalidation triggers should be clearly defined in the company's quality manual.

For Australian manufacturers planning to export, the same PQ data package often supports submissions to overseas regulators, including the US FDA and the European Medicines Agency. Keeping the documentation clean, complete, and aligned with international expectations from day one avoids costly rework later and supports faster approvals when the business expands into new markets.

Comparing the scope of OQ and PQ

The following summary clarifies how OQ and PQ differ in objective, materials, and acceptance criteria. Reviewing these distinctions helps validation managers avoid the common error of treating PQ as a repeat of OQ.

Aspect	Operational qualification (OQ)	Performance qualification (PQ)
Primary objective	Verify equipment functions within design specifications	Confirm process performs reliably under routine production conditions
Materials used	Placebo or simulated product	Actual API and excipients intended for market
Operators	Validation engineers and trained witnesses	Routine production staff who run commercial batches
Environment	Controlled, instrumented test conditions	Normal manufacturing environment
Typical challenges	Empty running, alarm tests, range verification, safety interlocks	Full batch runs with full sampling and stability testing
Acceptance criteria	Equipment specification and design limits	Pharmacopoeial and product release specifications
Regulatory alignment	Demonstrates fitness for intended use	Demonstrates reproducible commercial process

A practical extension of this comparison is to map each test back to a specific CQA and to the relevant clause of the Australian Code of GMP for Medicinal Products, which is fully aligned with PIC/S expectations. Validation teams that maintain this traceability matrix find it far easier to defend their work during pre-approval inspections and to identify which tests need repeating after any significant change.

Once PQ has been successfully completed and the validation report is approved, the new capsule filling machine can be released for commercial production. Training records should be updated to reflect that operators are now qualified on the released equipment, and the maintenance schedule should be integrated into the site's computerised maintenance management system. Some Australian manufacturers link their CMMS to the original equipment documentation, including the downstream packaging guidance that becomes relevant once capsules leave the filling line. The next process step typically involves secondary packaging, where cartoning machine formats and quick-change tooling directly influence overall line efficiency.

Selecting equipment that arrives with comprehensive factory acceptance testing and FAT data can shorten the on-site OQ phase by a week or more. Manufacturers sourcing machinery from suppliers such as Shanghai Huale Industrial Co., Ltd. often negotiate FAT attendance as part of the procurement contract, allowing Australian validation teams to observe tests in China before shipment. This reduces the burden of on-site testing and ensures that the machine is already familiar to the engineers who will qualify it. For a deeper look at the equipment portfolio available, including capsule filling lines designed for both R&D and commercial scales, prospective buyers can review detailed specifications before committing to a purchase order.